首页 / 院系成果 / 成果详情页

Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma 期刊论文

编号：

72df94e1-da98-43ae-b48c-bf41818dc545
作者：

Liang, Chen^[1,2,3];Qin, Yi^[1,2,3];Zhang, Bo(张波)^[1,2,3]Ji, Shunrong^[1,2,3];Shi, Si^[1,2,3];Xu, Wenyan^[1,2,3];Liu, Jiang^[1,2,3];Xiang, Jinfeng(项金峰)^[1,2,3]Liang, Dingkong^[1,2,3];Hu, Qiangsheng^[1,2,3];Ni, Quanxing^[1,2,3];Xu, Jin(徐近)^[1,2,3]Yu, Xianjun(虞先濬)^[1,2,3]
语种：

English
期刊：

MOLECULAR CANCER RESEARCH ISSN：1541-7786 2017 年 15 卷 2 期 (201 - 212) ; FEB
收录：
摘要：

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with the 5-year survival rate less than 6%. Previous results indicated that serum levels of CA125 (encoded by MUC16) could be used to predict which groups of pancreatic cancer patients may benefit from surgery. However, the underlying mechanism remains elusive. Herein, using the Cancer Genome Atlas and clinicopathologic data obtained from our center, we demonstrate that high CA125 serum levels and expression levels of MUC16 are predictive of poor prognosis. MUC16 is also validated as a downstream target of KRAS, and their expression strongly correlated with each other in vitro and in vivo. Mechanistically, the KRAS/ERK axis induced upregula-tion of MUC16 and shedding of CA125 via its effector c-Myc in SW1990 and PANC-1 pancreatic cancer cells. Notably, protooncogene c-Myc could bind to the promoter of MUC16 and transcriptionally activate its expression. Taken together, these data establish CA125 as a prognostic marker for pancreatic cancer, and mechanistic studies uncovered the KRAS/c-Myc axis as a driving factor for upregulation of MUC16. (C) 2016 AACR.
推荐引用方式
GB/T 7714：

Liang Chen,Qin Yi,Zhang Bo, et al. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma [J].MOLECULAR CANCER RESEARCH,2017,15(2):201-212.
APA：

Liang Chen,Qin Yi,Zhang Bo,Ji Shunrong,&Yu Xianjun.(2017).Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma .MOLECULAR CANCER RESEARCH,15(2):201-212.
MLA：

Liang Chen, et al. "Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma" .MOLECULAR CANCER RESEARCH 15,2(2017):201-212.

浏览次数：3  下载次数：0

分享到：

浏览次数：3

下载次数：0

打印次数：0